Abstract
Patient-derived tumor organoids (PDTOs) are novel cellular models that maintain the genetic, phenotypic and structural features of patient tumor tissue and are useful for studying tumorigenesis and drug response. When integrated with advanced 3D imaging and analysis techniques, PDTOs can be used to establish physiologically relevant high-throughput and high-content drug screening platforms that support the development of patient-specific treatment strategies. However, in order to effectively leverage high-throughput PDTO observations for clinical predictions, it is critical to establish a quantitative understanding of the basic properties and variability of organoid growth dynamics. In this work, we introduced an innovative workflow for analyzing and understanding PDTO growth dynamics, by integrating a high-throughput imaging deep learning platform with mathematical modeling, incorporating flexible growth laws and variable dormancy times. We applied the workflow to colon cancer organoids and demonstrated that organoid growth is well-described by the Gompertz model of growth. Our analysis showed significant intrapatient heterogeneity in PDTO growth dynamics, with the initial exponential growth rate of an organoid following a lognormal distribution within each dataset. The level of intrapatient heterogeneity varied between patients, as did organoid growth rates and dormancy times of single seeded cells. Our work contributes to an emerging understanding of the basic growth characteristics of PDTOs, and it highlights the heterogeneity in organoid growth both within and between patients. These results pave the way for further modeling efforts aimed at predicting treatment response dynamics and drug resistance timing.
Funder
National Cancer Institute
National Science Foundation
Norges Forskningsråd
Publisher
Public Library of Science (PLoS)
Reference49 articles.
1. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients;GE Wensink;NPJ Precis Oncol,2021
2. An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity;S Jiang;Cell Rep Med,2020
3. Drug screening at single-organoid resolution via bioprinting and interferometry;PJ Tebon;Nat Commun,2023
4. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer;AJ Walsh;Cancer Res,2014
5. Clinical translation of patient-derived tumour organoids-bottlenecks and strategies;MA Foo;Biomark Res,2022